Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03859700 · ClinicalTrials.gov registry record · Phase 3
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
A Phase 3 study, sponsored by DBV Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
NCT03859700: Completed Phase 3 study, sponsored by DBV Technologies.
NCT03859700 is a Phase 3 study that has completed, run by DBV Technologies. The registered enrollment target is 304 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03859700, a Phase 3 study, has completed, sponsored by DBV Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
Study Summary
Open-label, follow-up study for subjects who completed the EPITOPE study.
Interventions
- BIOLOGICAL DBV712 250 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2025-05-13 |
| Phase | Phase 3 |
What the finished NCT03859700 record still lists
NCT03859700 is an interventional study that assigns participants to a tested intervention. The registered 304 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 1 intervention - of which DBV712 250 mcg is the first listed.
NCT03859700 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03859700 about?
NCT03859700 is a clinical study titled "Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children". Open-label, follow-up study for subjects who completed the EPITOPE study.
What is the current status of trial NCT03859700?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2018-12-06. Estimated completion is 2025-05-13.
What interventions are being tested in trial NCT03859700?
The interventions under investigation include: DBV712 250 mcg (BIOLOGICAL).
Who is sponsoring clinical trial NCT03859700?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03859700's enrollment target sits among peer trials
304 1117th of 2000 higher than 882 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
- NCT06096844 · 304 participants · Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI